Kailera Therapeutics' IPO priced April 16 at the high end of its $14–$16 range, upsizing to 39 million shares for a record $625 million biotech raise, signaling robust institutional demand for its GLP-1/GIP obesity pipeline led by Phase 3 ribupatide. Shares debuted April 17 on Nasdaq (KLRA) at $26—63% above IPO price—closing at $26 amid high volume, implying a fully diluted market cap over $3 billion on 118 million shares outstanding, far exceeding the 2.1 billion threshold. Trader consensus at 99.4% for 2.1B+ reflects obesity sector momentum and recent positive topline data, with settlement April 20; a sharp biotech pullback or settlement hiccups could challenge it, though first-day strength minimizes risks.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated2.1B+ 99.4%
1.8B–1.9B <1%
2.0B–2.1B <1%
1.9B–2.0B <1%
$26,612 Vol.
$26,612 Vol.
Apr 17, 2026
1.8B–1.9B
1%
1.9B–2.0B
<1%
2.0B–2.1B
<1%
2.1B+
99%
2.1B+ 99.4%
1.8B–1.9B <1%
2.0B–2.1B <1%
1.9B–2.0B <1%
$26,612 Vol.
$26,612 Vol.
Apr 17, 2026
1.8B–1.9B
$2,327 Vol.
1%
1.9B–2.0B
$2,633 Vol.
<1%
2.0B–2.1B
$2,939 Vol.
<1%
2.1B+
$13,205 Vol.
99%
This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Kailera Therapeutics' IPO priced April 16 at the high end of its $14–$16 range, upsizing to 39 million shares for a record $625 million biotech raise, signaling robust institutional demand for its GLP-1/GIP obesity pipeline led by Phase 3 ribupatide. Shares debuted April 17 on Nasdaq (KLRA) at $26—63% above IPO price—closing at $26 amid high volume, implying a fully diluted market cap over $3 billion on 118 million shares outstanding, far exceeding the 2.1 billion threshold. Trader consensus at 99.4% for 2.1B+ reflects obesity sector momentum and recent positive topline data, with settlement April 20; a sharp biotech pullback or settlement hiccups could challenge it, though first-day strength minimizes risks.
This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Market Opened: Apr 14, 2026, 5:05 PM ET
Volume
$26,612End Date
Apr 17, 2026Market Opened
Apr 14, 2026, 5:05 PM ETResolver
0x69c47De9D...This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Kailera Therapeutics' IPO priced April 16 at the high end of its $14–$16 range, upsizing to 39 million shares for a record $625 million biotech raise, signaling robust institutional demand for its GLP-1/GIP obesity pipeline led by Phase 3 ribupatide. Shares debuted April 17 on Nasdaq (KLRA) at $26—63% above IPO price—closing at $26 amid high volume, implying a fully diluted market cap over $3 billion on 118 million shares outstanding, far exceeding the 2.1 billion threshold. Trader consensus at 99.4% for 2.1B+ reflects obesity sector momentum and recent positive topline data, with settlement April 20; a sharp biotech pullback or settlement hiccups could challenge it, though first-day strength minimizes risks.
This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volume
$26,612End Date
Apr 17, 2026Market Opened
Apr 14, 2026, 5:05 PM ETResolver
0x69c47De9D...Kailera Therapeutics' IPO priced April 16 at the high end of its $14–$16 range, upsizing to 39 million shares for a record $625 million biotech raise, signaling robust institutional demand for its GLP-1/GIP obesity pipeline led by Phase 3 ribupatide. Shares debuted April 17 on Nasdaq (KLRA) at $26—63% above IPO price—closing at $26 amid high volume, implying a fully diluted market cap over $3 billion on 118 million shares outstanding, far exceeding the 2.1 billion threshold. Trader consensus at 99.4% for 2.1B+ reflects obesity sector momentum and recent positive topline data, with settlement April 20; a sharp biotech pullback or settlement hiccups could challenge it, though first-day strength minimizes risks.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions